TULSA Abstracts at the 15th Interventional MRI Symposium Strengthen Real-World Evidence, Clinical Differentiation, and Platform Expansion Opportunity

TORONTO, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) today announced that five abstracts presented at the 15th Interventional MRI (“iMRI”) Symposium in Boston, Massachusetts, reinforce the growing body of evidence supporting the real-world performance, clinical differentiation, and platform expansion potential of the TULSA Procedure™ performed using the TULSA-PRO® system.

Collectively, the presentations underscore three important dimensions of TULSA’s progress:

- Real-world validation: Findings from the CARE Registry and single-center experiences at Mayo Clinic in Florida and Rochester provide complementary evidence of TULSA outcomes across multiple treatment strategies and clinical settings.

- Clinical differentiation: Results from the CAPTAIN randomized controlled trial demonstrate statistically superior preservation of erectile function together with pad-free continence with the TULSA Procedure compared with robotic radical prostatectomy (“robotic RP”) at six months.

-

Platform expansion potential: Technical validation on the Siemens 0.55T Free.Max MRI platform demonstrates the feasibility of delivering TULSA on a lower-field-strength MRI system, potentially broadening equipment options and reducing infrastructure barriers for future TULSA-PRO® adoption.*

“These presentations illustrate how TULSA’s evidence base is evolving across the dimensions that matter most: meaningful functional outcomes for patients, reproducibility in routine clinical practice, and the potential to extend our technology to a broader range of iMRI platforms,” said Mathieu Burtnyk, Chief Technology Officer of Profound Medical. “Together, they reinforce the differentiation of TULSA-PRO and its potential to support broader clinical adoption over time.”

Mayo Clinic Florida: Real-World Clinical Experience (Page 88)

This analysis reports experience from one of the early U.S. centers to incorporate TULSA-PRO into routine clinical practice, including 58 patients with up to 4.5 years of follow-up.

Patients underwent a range of treatment approaches, including focal, hemi-gland, subtotal and whole-gland ablation. Serious adverse events were uncommon, with no strictures or fistulas reported. Reported functional outcomes included 100% pad-free continence, 94% leak-free continence and preservation of erections sufficient for penetration in 87.5% of men beyond 12 months.

Median PSA nadir was 0.9 ng/mL, and 12% of patients required secondary prostate cancer treatment during follow-up.

These findings add longer-term clinical experience from routine practice to the growing TULSA evidence base, complementing the randomized CAPTAIN trial and multicenter CARE Registry. The results should be interpreted in the context of the study’s single-center design, patient selection and treatment heterogeneity.

Mayo Clinic Rochester: Prospective Single-Center Study (Page 89)

This prospective study evaluated 41 patients with biopsy-proven localized prostate cancer treated with the TULSA Procedure.

Mean PSA declined from 7.7 ng/mL at baseline to approximately 2.3–2.6 ng/mL, representing a sustained reduction of approximately 62%–66% through one year. The safety profile was generally manageable, with most adverse events involving urinary or sexual function.

Biopsy-confirmed recurrence was reported in 22% of patients, including 12% with in-field recurrence and 10% with out-of-field recurrence. The authors concluded that the TULSA Procedure provided substantial, sustained PSA reduction with a generally favorable safety profile.

The findings add prospective evidence from another high-volume Mayo Clinic center, complementing the broader CARE Registry and the randomized CAPTAIN trial. Together, these studies contribute to a more comprehensive understanding of TULSA’s performance across clinical settings, while underscoring the importance of continued follow-up to characterize oncologic durability.

CARE Registry: Treatment Extent, PSA Response and Catheterization Duration (Page 43)

This analysis evaluated 197 patients treated with the TULSA Procedure across five centers, with a median follow-up of 24 months.

The findings demonstrate the flexibility of TULSA treatment planning, spanning focal, subtotal and whole-gland ablation. As expected, more extensive ablation was associated with deeper prostate-specific antigen (“PSA”) reductions: median PSA nadir was 0.23 ng/mL following whole-gland treatment, compared with 0.60 ng/mL after subtotal treatment and 1.10 ng/mL after focal treatment.

Biochemical recurrence rates did not differ significantly across treatment extents in this analysis. Less extensive treatments were also associated with shorter catheterization duration, decreasing from a median of 13.5 days following whole-gland treatment to seven days following subtotal or focal treatment.

These findings highlight a key feature of the TULSA Procedure: the ability to individualize treatment extent, balancing the objectives of malignant tissue ablation, functional preservation and recovery according to patient needs and clinical judgment.

CAPTAIN Randomized Trial: TULSA Procedure vs. Robotic Radical Prostatectomy — Six-Month Outcomes (Page 42)

CAPTAIN (A Comparison of TULSA Procedure vs. Radical Prostatectomy in Participants with Localized Prostate Cancer) is the first fully enrolled, multicenter randomized controlled trial directly comparing the TULSA Procedure with robotic RP in patients with localized intermediate-risk prostate cancer.

As previously reported, whole-gland TULSA demonstrated perioperative advantages over robotic RP, including no blood loss, no overnight hospitalization, faster recovery and earlier return to work. Hospitalizations for complications were also substantially lower with whole-gland TULSA than with robotic RP (0.7% versus 6.3%).

At the primary six-month functional endpoint, whole-gland TULSA achieved statistically superior outcomes, with patients more than twice as likely to preserve both erectile function and pad-free continence (risk ratio of 2.1; p=0.004). Whole-gland TULSA also demonstrated statistically superior preservation of flaccid penile length at one month compared with robotic RP.

While oncologic outcomes continue to mature, these findings provide important randomized evidence of whole-gland TULSA’s potential to improve peri-operative outcomes and preserve quality of life.

Technical Validation of TULSA on the Siemens 0.55T Free.Max MRI Platform (Page 87)

Investigators successfully validated the technical feasibility of the TULSA Procedure on Siemens’ 0.55T Free.Max MRI platform, a lower-field-strength MRI system that may potentially offer additional options for future TULSA-PRO installations.*

The evaluation incorporated new three-dimensional thermometry protocols that improved temperature-measurement precision by 40% compared with conventional approaches. Temperature-monitoring performance approached that of conventional 1.5T systems, with baseline uncertainty of approximately ±1.1°C. Prostate anatomy and surrounding structures remained clearly visible using biparametric MRI protocols, while simulated treatments demonstrated targeting accuracy of 1.0 ± 0.9 mm.

This technical validation represents a potentially important step toward expanding the range of MRI systems on which TULSA could be deployed. If translated into clinical and commercial use, compatibility with lower-cost, wide-bore MRI systems could help reduce equipment-related infrastructure barriers, broaden the potential TULSA-PRO installed-base opportunity and mitigate susceptibility artifacts associated with implants such as hip prostheses.

*Technical feasibility does not establish U.S. Food and Drug Administration clearance, clinical validation or commercial availability on this combined TULSA-PRO>Siemens 0.55T Free.Max platform. Any statements regarding future deployment remain subject to further development and applicable regulatory requirements.

Building the Evidence and Expanding the Opportunity

“Our focus is to translate TULSA’s clinical differentiation into a broader opportunity for patients, physicians and healthcare providers,” said Profound’s Chief Executive Officer and Chairman, Arun Menawat. “The evidence presented at this year’s iMRI Symposium reinforces the potential of the TULSA Procedure becoming a mainstream treatment modality across the entire prostate disease spectrum, while our technical progress on lower-field-strength Siemens Free.Max points to a potential path toward reducing potential infrastructure barriers to more widespread adoption over time.”

About Profound Medical Corp.

Profound is a commercial-stage medical device company and an innovator in interventional MRI (iMRI) procedures. The company’s flagship platform, TULSA-PRO®, enables MRI-guided, incision-free prostate ablation. Physicians use the TULSA Procedure™ to see, ablate, and confirm therapy in real time, supporting personalized treatment strategies across the continuum of prostate care—from whole-gland to subtotal, hemi, multifocal, and focal treatment. This approach enables individualized care using prostate tissue ablation, while minimizing the potential of the side effects that are typically associated with surgery or radiation, such as urinary incontinence and/or erectile dysfunction.

Profound also commercializes Sonalleve®, an MRI-guided therapy that provides a non-surgical treatment option for pain palliation of bone metastases, desmoid tumors, and osteoid osteoma, as well as for common gynecologic conditions including uterine fibroids and adenomyosis.

Neusoft Selected into 2026 IDC China FinTech Power Force 50 List

SHENYANG, China, Oct. 14, 2026 /PRNewswire/ -- Neusoft Corporation (SSE: 600718), an industry-leading information technology, products and solutions company for the global market, has been recognized in the 2026 IDC China FinTech Power Force 50 ranking, released recently by International Data Corporation (IDC).

The annual IDC China FinTech Power Force 50 selection specifically focuses on technology providers that have already achieved large-scale service capabilities and proven mature business models. This year's ranking evaluates candidates against four criteria: verified business maturity and market adoption, end-to-end full-link service delivery capabilities, independent technology development and regulatory compliance competence, as well as industry impact and ecosystem contribution.

Neusoft's inclusion in the list recognizes its leading industry competitiveness in core banking systems, AI-powered intelligent risk control, and look-through regulatory compliance solutions. It demonstrates that Neusoft, equipped with both self-developed underlying platforms and deep vertical industry expertise, has established itself as a reliable, trusted provider for mission-critical financial services operations.

Neusoft's competitive edge in financial risk management and compliance software is underpinned by the company's two cross-sector, highly transferable core strengths that have been refined over 30 years across multiple highly regulated industries: a proven full-stack capability to convert complex, distributed enterprise data into measurable business value, and field-validated expertise in deploying artificial intelligence responsibly with built-in governance.

As China's fintech industry enters deep-water development phase, the market has a growing demand for providers with robust underlying technology, deep understanding of both business and regulatory requirements, and a proven track record of building long-term partnerships. With three decades of accumulated data capabilities and AI implementation expertise, Neusoft stands out to meet the market demands, and is well-positioned to unlock new value growth opportunities in the period ahead.

For more information about Neusoft, please visit www.neusoft.com.

SOURCE Neusoft Corporation

Share this article

Slimmer Smart Glasses, Full Eye Tracking: Viewpointsystem Brings the Entire Pipeline to the Edge

- Viewpointsystem is the first to bring to market a complete image-based eye-tracking pipeline that runs directly on an ultra-low-power microcontroller (MCU) inside the glasses frame

- The MCU powers Viewpointsystem's compact, ready-to-integrate Digital Iris® Module, delivering 140 Hz eye tracking without requiring a powerful application processor

- Full edge processing reduces power consumption, heat and hardware requirements, enabling up to 15 times longer battery runtime and slimmer, lighter smart glasses

VIENNA, Oct. 14, 2026 /PRNewswire/ -- Viewpointsystem gives smart-glasses manufacturers (OEMs) a new way to add advanced eye tracking without compromising on battery life, heat or design. Until now, power consumption, heat generation and limited space have made it difficult to bring eye tracking into lightweight smart glasses. Viewpointsystem's new implementation of its Digital Iris Module, powered by an ultra-low-power Ensemble MCU from edge AI pioneer Alif Semiconductor, removes this hurdle: the market-ready module runs the entire image-based eye-tracking pipeline at 140 Hz directly inside the glasses frame.

This MCU-based architecture makes integration considerably easier: OEMs no longer need a high-end application processor for eye tracking, yet the module remains fully compatible with existing application processors. Thanks to its integrated neural processing unit (NPU) for efficient AI processing, the programmable MCU can also run additional AI-based functions. At the same time, the architecture lowers power and processing demands and keeps sensitive eye-camera images safely on the chip.

"Eye tracking belongs in smart glasses, and it has to fit into the thinnest, lightest designs. By moving the entire processing pipeline to the edge, we're giving smart-glasses OEMs the flexibility to integrate eye tracking across a wider range of designs, with or without a high-end application processor," said Nils Berger, CEO and Founder of Viewpointsystem.

How the Technology Works

Conventional eye-tracking systems typically transfer images from eye-facing cameras to a main application processor in the glasses or a connected device. Processing these image streams consumes power, generates heat and adds to system complexity – a particular challenge for compact, battery-powered eyewear.

Viewpointsystem's Digital Iris Module combines two optimally positioned eye-facing cameras with the MCU in a compact hardware unit designed to fit into the bridge of the glasses frame. The MCU handles the complete processing pipeline, from image preprocessing and NPU-accelerated gaze calculation to real-time detection of eye events such as blinks, fixations and saccades. Instead of transmitting camera images, it delivers ready-to-use gaze data for real-time attention and focus tracking, as well as applications assessing brain health, cognitive changes and neurological function.

Key Benefits for Smart-Glasses OEMs

- Lower power consumption, longer battery life: Performance measurements indicate up to 15 times longer battery runtime compared with conventional eye-tracking processing on a connected device. Reduced heat generation further supports compact, comfortable designs.

- Performance on the edge: The MCU delivers eye-tracking rates of 140 Hz, with the potential to reach up to 400 Hz depending on customer requirements and use cases. It also acquires and fuses data from additional on-board sensors, including an ambient light sensor, magnetometer, and accelerometer, directly on the edge, while freeing the main processor for other tasks or low-power states.

- Easy integration and design flexibility: The ready-to-integrate Digital Iris Module combines hardware and software, reduces development effort for OEMs, and can be adapted to fit different smart-glasses designs.

- Privacy and AI capabilities: Only gaze data leaves the MCU, keeping sensitive eye images on-chip. The programmable MCU can also support additional workloads, including AI-based functions.

"Viewpointsystem's implementation demonstrates how our Ensemble MCU can handle demanding real-time vision processing within the tight power and space constraints of smart glasses," said Mark Rootz, VP Global Marketing at Alif Semiconductor. "This is exactly what we built the Ensemble family for: real-time AI at the edge without the power and thermal overhead of an application processor."

The patented MCU-based solution now opens up new opportunities for eye tracking in smart glasses where power, space and processing constraints have so far ruled it out – from lightweight AI and AR glasses to display-less eyewear and specialized industrial applications.

- Picture is available at AP -

About Viewpointsystem

Viewpointsystem is a Vienna-based deep-tech company that develops and manufactures internationally recognized smart glasses with eye tracking for applications in manufacturing, transportation, research and defense. Its DIGITAL IRIS® technology enables smart-glasses OEMs to integrate advanced eye tracking into their products, paving the way for more intuitive human-computer interaction. Viewpointsystem is a member of the Qualcomm Partner Network and the AR Alliance. viewpointsystem.com

Media Contact

Jana Riethausen

PR & Corporate Communications

Viewpointsystem GmbH

+43 660 90 50 515

[email protected]

SOURCE Viewpointsystem

Share this article

FitVille Launches Rebound Nova Walking Shoes Featuring Triple-Density Cushioning and Wide-Fit Comfort

A new walking shoe collection blends Dyno Foam™ triple-density cushioning, ergonomic support, and improved traction, all in an everyday design.

NEWARK, Del., Oct. 14, 2026/PRNewswire/ -- FitVille has expanded its wide-fit footwear lineup with the new Rebound Nova Collection, featuring Dyno Foam™, a triple-density cushioning system designed to balance comfort, stability, and responsiveness for everyday walking.

Six Models, One Comfort-First Approach

The Rebound Nova Collection includes six models: Men's Rebound Apex, Rebound Nova, Rebound Nova Elite, Rebound Nova Edge, Rebound Nova Grand, and Rebound Summit.

With widths available up to 4E, the collection provides extra room around the forefoot and toes without compromising modern styling or support.

Dyno Foam™: Three Densities for Targeted Cushioning

Unlike earlier Rebound Core and Neo models, which use dual-density EVA foam, Rebound Nova introduces three foam densities: 53C, 55C, and 58C.

The softer 53C foam cushions the forefoot, the intermediate 55C layer supports smooth transitions, and the firmer 58C heel helps provide stability and impact control. Together, these densities create a more balanced cushioning experience.

Wide-Fit Engineering Meets Enhanced Traction

Rebound Nova combines its wider fit with a 3-in-1 Ergonomic Insole System designed for cushioning, ventilation, and arch support. Its Eight-Point Traction Outsole features eight strategically positioned support areas to improve ground contact.

According to FitVille's internal testing, the outsole delivers 20% more traction while reducing weight by 20%.

Modern Style for Everyday Movement

With streamlined silhouettes, clean details, and versatile colors, Rebound Nova brings a contemporary look to wide-fit walking shoes. The collection is designed for daily walks, shopping, work shifts, and extended periods of standing.

"FitVille has always focused on two things: creating footwear that accommodates the whole foot and finding better ways to deliver real comfort," said James D. Kuai, Founder and CEO of FitVille.

The Rebound Nova Collection combines FitVille's wide-fit expertise with upgraded cushioning and traction technology. All six models are available through FitVille's official website.

Founded in 2018, FitVille specializes in wide and therapeutic footwear for diabetes, bunions, arthritis, and plantar fasciitis. Combining American design with expert Asian manufacturing, its Comfort+™, PropelCore™, and ErgoFit™ technologies deliver durable support and comfort. Guided by "Liberate Your Toes with Comfortable Shoes," FitVille advances foot health worldwide.

"Press Release Service" should be linked to https://www.24-7pressrelease.com/.

SOURCE FitVille

Share this article

Highlights for the Three Months Ended August31, 2026

- Total revenues of $283 million and net income of $69 million

- Adjusted EBITDA(1) of $247 million

- Acquired 5 aircraft for $269 million, including 3 Airbus A321neo and 1 Boeing 737MAX8

- Sold 11 aircraft and other flight equipment for proceeds of $243 million and gains on sales of $38 million

- New technology aircraft comprised 54% of our fleet's net book value as of August 31, 2026

Liquidity

- Redeemed all 400 outstanding Series A Preference Shares

- 98% of total debt is unsecured as of August 31, 2026

- Adjusted net debt-to-equity of 2.4 times as of August 31, 2026

- Total liquidity of $2.8 billion as of October 1, 2026, which includes $2.0 billion of undrawn facilities, $0.7 billion of projected adjusted operating cash flows and sales through October 1, 2027, and $0.1 billion of unrestricted cash

- 259 unencumbered aircraft and other flight equipment with a net book value of $8.2 billion

STAMFORD, Conn., Oct. 14, 2026 /PRNewswire/ -- Mike Inglese, Aircastle's CEO stated, "Strong travel demand and constrained aircraft supply continue to support lease rates and asset values.  Significant gains on sale contributed to second quarter net income of $69 million, reinforcing a disciplined, profitability-focused approach to capital deployment.  Year-to-date, we've invested $386 million in aircraft acquisitions and we're moving into the second half of our fiscal year with ample liquidity and confidence in our ability to service our customers and source attractive investments."

Aviation Assets

As of August 31, 2026, Aircastle owned 263 aircraft and other flight equipment having a net book value of $8.3 billion and managed an additional 5 aircraft.

Conference Call

Following this press release, management will host a conference call on Wednesday, October 14, 2026, at 9:00 A.M. Eastern Time.  All interested parties are welcome to participate in the live call.  The conference call can be accessed by dialing 1 (800) 836-8184 (from within the U.S. and Canada) or +1 (646) 357-8785 (outside the U.S. and Canada) ten minutes prior to the scheduled start. Please reference our company name "Aircastle" when prompted by the operator.

A simultaneous webcast of the conference call will be available to the public on a listen-only basis at www.aircastle.com.  Please allow extra time prior to the call to visit the site and download the necessary software required to listen to the internet broadcast. 

For those who are not available to listen to the live call, a replay will be available on Aircastle's website shortly after the live call.

About Aircastle Limited

Aircastle Limited acquires, leases and sells commercial jet aircraft to airlines throughout the world.  As of August 31, 2026, Aircastle owned and managed 268 aircraft leased to 67 airline customers located in 42 countries.

Safe Harbor

All statements in this press release, other than characterizations of historical fact, are forward-looking statements within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995.  Examples of forward-looking statements include, but are not necessarily limited to, statements relating to our proposed public offering of notes and our ability to acquire, sell, lease or finance aircraft, raise capital, pay dividends and increase revenues, earnings, EBITDA and Adjusted EBITDA and the global aviation industry and aircraft leasing sector. Words such as "anticipates," "expects," "enables," "intends," "plans," "positions," "projects," "believes," "may," "will," "would," "could," "should," "seeks," "estimates" and variations on these words and similar expressions are intended to identify such forward-looking statements.  These statements are based on our historical performance and that of our subsidiaries and on our current plans, estimates and expectations and are subject to a number of factors that could lead to actual results being materially different from those described in the forward-looking statements; Aircastle can give no assurance that its expectations will be attained.  Accordingly, you should not place undue reliance on any such forward-looking statements which are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated as of the date of this press release.  These risks or uncertainties include, but are not limited to, those described from time to time in Aircastle's filings with the SEC and previously disclosed under "Risk Factors" in Item 1A of Aircastle's most recent Form 10-K and any subsequent filings with the SEC.  In addition, new risks and uncertainties emerge from time to time, and it is not possible for Aircastle to predict or assess the impact of every factor that may cause its actual results to differ from those contained in any forward-looking statements.  Such forward-looking statements speak only as of the date of this press release.  Aircastle expressly disclaims any obligation to revise or update publicly any forward-looking statement to reflect future events or circumstances.

We define EBITDA as income (loss) from continuing operations before income taxes, interest expense, and depreciation and amortization.  We use EBITDA to assess our consolidated financial and operating performance, and we believe this non-U.S. GAAP measure is helpful in identifying trends in our performance.

This measure provides an assessment of controllable expenses and affords management the ability to make decisions which are expected to facilitate meeting current financial goals, as well as achieving optimal financial performance.  It provides an indicator for management to determine if adjustments to current spending decisions are needed.

EBITDA provides us with a measure of operating performance because it assists us in comparing our operating performance on a consistent basis as it removes the impact of our capital structure (primarily interest charges on our outstanding debt) and asset base (primarily depreciation and amortization) from our operating results.  Accordingly, this metric measures our financial performance based on operational factors that management can impact in the short-term, namely the cost structure, or expenses, of the organization.  EBITDA is one of the metrics used by senior management and the Board of Directors to review the consolidated financial performance of our business.

We define Adjusted EBITDA as EBITDA (as defined above) further adjusted to give effect to adjustments required in calculating covenant ratios and compliance as that term is defined in the indenture governing our senior unsecured notes.  Adjusted EBITDA is a material component of these covenants.

Contact:

Aircastle (Ireland) DAC (US)

Jim Connelly, SVP ESG & Corporate Communications

Tel: +1-203-504-1871

[email protected]

SOURCE Aircastle Ireland DAC

Share this article

—Three Late-Breaking Abstracts at CHEST 2026 Deepen Understanding of the Potential of Treprostinil Palmitil Inhalation Powder (TPIP) Across Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)—

—New Analysis From the Phase 3 ASPEN Study at CHEST 2026 Provides Additional Insights on Bronchiectasis Management—

—Phase 3b ENCORE Study Findings at IDWeek 2026 Examine Amikacin and Macrolide Resistance Development in Patients With Newly Diagnosed Mycobacterium avium Complex (MAC) Lung Disease—

BRIDGEWATER, N.J., Oct. 14, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced new data from its respiratory portfolio will be presented at the American College of Chest Physicians® Annual Meeting 2026 (CHEST 2026), taking place Oct. 18–21 in Phoenix, and IDWeek 2026, taking place Oct. 21–24 in Washington, D.C.

"This fall medical congress season is a powerful reminder of what's possible when we stay focused on delivering meaningful solutions for patients who need them most," said Martina Flammer, M.D., MBA, Chief Medical Officer of Insmed. "From CHEST 2026 to IDWeek 2026, we're proud to share data across our respiratory portfolio, including BRINSUPRI, TPIP, and ARIKAYCE. Altogether, these presentations reflect the strength and diversity of our growing respiratory portfolio and our unwavering dedication to advancing critical therapies that have the potential to benefit the patients we aim to serve."

Insmed's Presence at CHEST 2026

Presentation highlights at CHEST 2026 include four abstracts from the treprostinil palmitil inhalation powder (TPIP) clinical development program, including three late-breaking abstracts that offer new insights into the long-term potential of TPIP in pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Additionally, a post hoc analysis of the Phase 3 ASPEN study of BRINSUPRI® (brensocatib) — the first and only approved treatment for non-cystic fibrosis bronchiectasis (NCFB) — examines patient-reported sputum color and its association with neutrophil serine proteases and exacerbations.

The Insmed presentations at CHEST 2026 are as follows:

Top Late-Breaking Abstracts: New Drugs, New Targets, New Tools, Session ID 4145, Tuesday, Oct. 20, 2026, 11:15 a.m. MT to 12:15 p.m. MT (2:15 p.m. ET to 3:15 p.m. ET)

Late-Breaking Scientific Abstract Posters (B): Pulmonary Vascular Disease, Sleep Disorders, Poster 3219, Tuesday, Oct. 20, 2026, 1:45 p.m. MT to 2:30 p.m. MT (4:45 p.m. ET to 5:30 p.m. ET)

Late-Breaking Scientific Abstract Posters (B): Pulmonary Vascular Disease, Sleep Disorders, Poster 3224, Tuesday, Oct. 20, 2026, 1:45 p.m. MT to 2:30 p.m. MT (4:45 p.m. ET to 5:30 p.m. ET)

Pulmonary Vascular Disease Scientific Abstract Posters (C): PAH, Poster 3503, Tuesday, Oct. 20, 2026, 1:45 p.m. MT to 2:30 p.m. MT (4:45 p.m. ET to 5:30 p.m. ET)

Rapid Fire Original Investigation, CF and Non-CF Bronchiectasis Management, Session ID 4146, Monday, Oct. 19, 2026, 10:20 a.m. MT to 10:50 a.m. MT (1:20 p.m. ET to 1:50 p.m. ET)

Insmed's Presence at IDWeek 2026

Insmed will present two abstracts at IDWeek 2026 on ARIKAYCE® (amikacin liposome inhalation suspension), including data from the Phase 3b ENCORE study examining amikacin and macrolide resistance development in patients with newly diagnosed Mycobacterium avium complex (MAC) lung disease. A second presentation will examine real-world evidence on treatment drivers and outcomes in patients diagnosed with MAC lung disease.

Insmed presentations at IDWeek 2026 are as follows:

Antimicrobials, LB-2201.1, Thursday, Oct. 22, 2026, 10:30 a.m. ET to 10:42 a.m. ET

Respiratory Infections: Viral and Bacterial, P-475, Saturday, Oct. 24, 2026, 12:15 p.m. ET to 1:30 p.m. ET

About ARIKAYCE

ARIKAYCE® is approved in the United States as ARIKAYCE (amikacin liposome inhalation suspension), in Europe as ARIKAYCE Liposomal 590 mg Nebuliser Dispersion, and in Japan as ARIKAYCE inhalation 590 mg (amikacin sulfate inhalation drug product). Current international treatment guidelines recommend the use of ARIKAYCE for appropriate patients. ARIKAYCE is a novel, inhaled, once-daily formulation of amikacin, an established antibiotic that was historically administered intravenously and associated with severe toxicity to hearing, balance, and kidney function. Insmed's proprietary PULMOVANCE™ liposomal technology enables the delivery of amikacin directly to the lungs, where liposomal amikacin is taken up by lung macrophages where the infection resides, while limiting systemic exposure. ARIKAYCE is administered once daily using the Lamira® Nebulizer System manufactured by PARI Pharma GmbH (PARI).

About PARI Pharma and the Lamira® Nebulizer System

ARIKAYCE is delivered by a novel inhalation device, the Lamira® Nebulizer System, developed by PARI. Lamira® is a quiet, portable nebulizer that enables efficient aerosolization of ARIKAYCE via a vibrating, perforated membrane. Based on PARI's 100-year history working with aerosols, PARI is dedicated to advancing inhalation therapies by developing innovative delivery platforms to improve patient care.

About BRINSUPRI

BRINSUPRI® (brensocatib) is a small molecule, once-daily, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), designed to inhibit the activation of enzymes (neutrophil serine proteases) in neutrophils that are key drivers of chronic airway inflammation in non-cystic fibrosis bronchiectasis (NCFB). The therapy is approved in the United States as BRINSUPRI (brensocatib 10 mg and 25 mg tablets) and indicated for the treatment of NCFB in adult and pediatric patients 12 years of age or older. In the European Union and United Kingdom, BRINSUPRI (brensocatib 25 mg tablets) is approved for the treatment of NCFB in patients 12 years of age and older with two or more exacerbations in the prior 12 months. In Japan, BRINSUPRI Tablets 25 mg (brensocatib hydrate) is approved for the treatment of NCFB in adults and pediatric patients 12 years and older.

About TPIP

Treprostinil palmitil inhalation powder (TPIP) is an investigational dry powder formulation of treprostinil palmitil, a treprostinil prodrug consisting of treprostinil linked by an ester bond to a 16-carbon chain. Designed entirely in Insmed's laboratories, TPIP is a potentially highly differentiated prostanoid being developed as once-daily therapy for the treatment of patients with pulmonary arterial hypertension (PAH), pulmonary hypertension associated with interstitial lung disease (PH-ILD), progressive pulmonary fibrosis (PPF), and idiopathic pulmonary fibrosis (IPF). TPIP is administered in a capsule-based inhalation device. TPIP is an investigational drug product that has not been approved for any indication in any jurisdiction.

BOXED WARNING AND IMPORTANT SAFETY INFORMATION FOR ARIKAYCE IN THE U.S.

Hypersensitivity Pneumonitis has been reported with the use of ARIKAYCE in the clinical trials. Hypersensitivity pneumonitis (reported as allergic alveolitis, pneumonitis, interstitial lung disease, allergic reaction to ARIKAYCE) was reported at a higher frequency in patients treated with ARIKAYCE plus background regimen (3.1%) compared to patients treated with a background regimen alone (0%). Most patients with hypersensitivity pneumonitis discontinued treatment with ARIKAYCE and received treatment with corticosteroids. If hypersensitivity pneumonitis occurs, discontinue ARIKAYCE and manage patients as medically appropriate.

Hemoptysis has been reported with the use of ARIKAYCE in the clinical trials. Hemoptysis was reported at a higher frequency in patients treated with ARIKAYCE plus background regimen (17.9%) compared to patients treated with a background regimen alone (12.5%). If hemoptysis occurs, manage patients as medically appropriate.

Bronchospasm has been reported with the use of ARIKAYCE in the clinical trials. Bronchospasm (reported as asthma, bronchial hyperreactivity, bronchospasm, dyspnea, dyspnea exertional, prolonged expiration, throat tightness, wheezing) was reported at a higher frequency in patients treated with ARIKAYCE plus background regimen (28.7%) compared to patients treated with a background regimen alone (10.7%). If bronchospasm occurs during the use of ARIKAYCE, treat patients as medically appropriate.

Exacerbations of underlying pulmonary disease has been reported with the use of ARIKAYCE in the clinical trials. Exacerbations of underlying pulmonary disease (reported as chronic obstructive pulmonary disease (COPD), infective exacerbation of COPD, infective exacerbation of bronchiectasis) have been reported at a higher frequency in patients treated with ARIKAYCE plus background regimen (14.8%) compared to patients treated with background regimen alone (9.8%). If exacerbations of underlying pulmonary disease occur during the use of ARIKAYCE, treat patients as medically appropriate.

Anaphylaxis and Hypersensitivity Reactions: Serious and potentially life-threatening hypersensitivity reactions, including anaphylaxis, have been reported in patients taking ARIKAYCE. Signs and symptoms include acute onset of skin and mucosal tissue hypersensitivity reactions (hives, itching, flushing, swollen lips/tongue/uvula), respiratory difficulty (shortness of breath, wheezing, stridor, cough), gastrointestinal symptoms (nausea, vomiting, diarrhea, crampy abdominal pain), and cardiovascular signs and symptoms of anaphylaxis (tachycardia, low blood pressure, syncope, incontinence, dizziness). Before therapy with ARIKAYCE is instituted, evaluate for previous hypersensitivity reactions to aminoglycosides. If anaphylaxis or a hypersensitivity reaction occurs, discontinue ARIKAYCE and institute appropriate supportive measures.

EcoPhage and Agricultura Nacional Sign a Distribution Agreement for Mexico

Strategic partnership will bring EcoPhage's phage-based biological crop protection solutions to Mexican growers

REHOVOT, Israel, Oct. 14, 2026 /PRNewswire/ -- EcoPhage, a leader in the development of sustainable phage-based biopesticides for the control of bacterial plant diseases, today announced that it has entered into a distribution agreement with Agricultura Nacional, S.A. de C.V. ("Dragon") for the distribution, marketing and sale of EcoPhage's products in Mexico.

The agreement marks an important milestone in EcoPhage's international commercial expansion and establishes Dragon as EcoPhage's distribution partner in Mexico, subject to the achievement of agreed commercial targets.

Under the agreement, Dragon will initially distribute GoldenEco® and EcoFire®, two of EcoPhage's phage-based biological crop protection products designed to address important bacterial diseases affecting agricultural crops.

Bacterial diseases represent a significant challenge for growers worldwide, while available disease-management programs have traditionally relied heavily on copper-based products and, in certain applications, antibiotics. Growing concerns around resistance, environmental impact, residues and evolving regulatory requirements are increasing the demand for innovative biological alternatives.

EcoPhage's proprietary technology platform uses naturally occurring bacteriophages—viruses that specifically target and destroy bacteria—to develop targeted biological solutions for bacterial plant diseases.

The company's pipeline includes products designed for multiple crops and bacterial pathogens, with the objective of providing growers with effective, targeted and sustainable tools that can complement existing crop-protection programs.

GoldenEco®, EcoPhage's flagship product that was approved recently by the EPA in the USA, is being developed for the management of bacterial diseases in tomatoes and peppers. The product is based on bacteriophage technology and is designed to provide growers with a biological approach to bacterial disease management. EcoFire® is another product in EcoPhage's expanding portfolio of phage-based solutions, targeting bacterial disease management in fruit crops.

Through the agreement, Dragon will be responsible for the marketing and distribution of EcoPhage's products throughout Mexico, working to establish the products in the local agricultural market and expand access to phage-based biological crop protection solutions.

The partnership combines EcoPhage's proprietary phage technology and product development capabilities with Dragon's local market expertise, commercial infrastructure and agricultural relationships, creating a platform for the introduction and expansion of innovative biological crop protection solutions in Mexico.

Martin Fueyo Mac Donald, Dragon's CEO, said: "We are excited to partner with EcoPhage and bring its innovative phage-based technology to the Mexican agricultural market. The demand for effective and sustainable crop protection solutions continues to grow, and we believe EcoPhage's technology offers an important new approach to bacterial disease management. We look forward to working closely with EcoPhage to introduce these solutions to Mexican growers and build a strong commercial presence in the market."

"We are very pleased to enter into this strategic partnership with Dragon," added Guy Elitzur, CEO of EcoPhage. "Mexico is an important agricultural market with significant potential for biological crop protection solutions, and we believe Dragon is the right partner to introduce and develop our technology in the country. This agreement represents an important step in our global commercialization strategy and brings EcoPhage closer to growers who are looking for new and sustainable solutions to manage bacterial diseases."

The partnership reflects the growing importance of biological solutions as part of integrated crop protection programs. By providing growers with access to targeted, phage-based products, EcoPhage and Dragon aim to support the development of more sustainable disease-management programs and provide additional tools that can help reduce reliance on conventional approaches where appropriate.

"Our vision is to build a global platform of biological solutions for bacterial diseases," added Elitzur. "The partnership with Dragon is an important part of that vision. We are not only introducing individual products to a new market; we are building a long-term commercial platform that can support the introduction of additional EcoPhage technologies and products to Mexican agriculture."

About Agricultura Nacional, S.A. de C.V.

Agricultura Nacional, S.A. de C.V. (ANSA) is a Mexican agricultural company serving the country's crop protection and agricultural markets. Through its commercial capabilities and local market expertise, ANSA provides agricultural solutions to growers and supports the adoption of innovative technologies in Mexican agriculture.

About EcoPhage

EcoPhage is an agricultural biotechnology company developing innovative biological solutions for the control of bacterial plant diseases. Based on its proprietary phage discovery and development platform, EcoPhage develops targeted, natural, non-GMO and zero-residue biopesticides designed to provide effective disease management across a broad range of crops.

The company is advancing a growing pipeline of phage-based products targeting important bacterial diseases and is focused on delivering sustainable solutions that support growers and the future of modern agriculture.

Media Contact:

Email: [email protected]

SOURCE EcoPhage

Share this article

Bank of America Reports Third Quarter 2026 Financial Results

CHARLOTTE, N.C., Oct. 14, 2026 /PRNewswire/ -- Bank of America reported its third quarter 2026 financial results today. The news release, supplemental filing and investor presentation can be accessed at Bank of America's Investor Relations website at https://investor.bankofamerica.com/quarterly-earnings.

A Form 8-K containing Bank of America's financial results is also available at the U.S. Securities and Exchange Commission's website at https://www.sec.gov.

Investor Conference Call information

Chair and CEO Brian Moynihan and Executive Vice President and CFO Alastair Borthwick will discuss the financial results in an investor conference call at 8:30 a.m. ET today. For a listen-only connection to the conference call, dial 1.877.200.4456 (U.S.) or 1.785.424.1732 (international), and the conference ID is 79795. Please dial in 10 minutes prior to the start of the call.

Investors can listen to live audio of the conference call and view the presentation slides by visiting the "Events and Presentations" section of the company's Investor Relations website.

Replay information for Investor Conference Call

Investors can access replays of the investor conference call by visiting the Investor Relations website or by calling 1.800.934.4850 (U.S.) or 1.402.220.1178 (international) from noon on October 14 through 11:59 p.m. ET on October 23. 

Bank of America

Bank of America is one of the world's leading financial institutions, serving individual consumers, small and middle-market businesses and large corporations with a full range of banking, investing, asset management and other financial and risk management products and services. The company provides unmatched convenience in the United States, serving more than 69 million clients with approximately 3,500 retail financial centers, approximately 15,000 ATMs (automated teller machines) and award-winning digital banking with approximately 60 million verified digital users. Bank of America is a global leader in wealth management, corporate and investment banking and trading across a broad range of asset classes, serving corporations, governments, institutions and individuals around the world. As the #1 small business lender in the United States (FDIC), Bank of America offers industry-leading support to approximately 4 million small business households through a suite of innovative, easy-to-use online products and services. The company serves clients through operations across the United States, its territories and more than 35 countries and/or jurisdictions. Bank of America Corporation stock (NYSE: BAC) is listed on the New York Stock Exchange.

Investors may contact

Lee McEntire, Bank of America

Phone: 1.980.388.6780

[email protected]

Jonathan G. Blum, Bank of America (Fixed Income)

Phone: 1.212.449.3112

[email protected]

Reporters may contact

Jocelyn Seidenfeld, Bank of America

Phone: 1.646.743.3356

[email protected] 

SOURCE Bank of America Corporation

Share this article

TELUS Digital Partners with Parloa to Help Enterprises Build and Manage AI Agents for Stronger Customer Relationships

Collaboration pairs Parloa's platform with TELUS Digital's customer experience expertise to help improve first impressions, deepen engagement and create value for enterprises and their customers

VANCOUVER, BC, Oct. 14, 2026 /PRNewswire/ -- TELUS Digital, a global technology service provider specializing in AI-powered digital customer experiences (CX) and future-focused digital transformations, today announced a partnership with Parloa, the leading agentic CX enabler for the enterprise. Established in Germany, Parloa brings a robust European enterprise footprint and experience supporting deployments subject to the General Data Protection Regulation (GDPR) and other European regulatory requirements, while TELUS Digital offers its existing delivery presence and regulated-industry expertise across North America and Europe.

TELUS Digital will serve as an implementation partner, introducing prospective and current enterprise clients to Parloa's AI agent platform and helping them put it into production at scale. Enterprises that choose to deploy Parloa can contract directly with the company for the platform itself and engage TELUS Digital for implementation, integration, change management, managed services and other professional services.

Parloa's AI agents handle customer interactions such as authentication, bookings, payments and order inquiries from beginning to end, and escalate to a human agent when a conversation calls for high-touch care. Parloa's own research, a study evaluating 10,000 enterprise websites and 4,000 chat interactions, found that fewer than 9% of chatbot conversations reached resolution, and only about 10% of escalation attempts actually reached a human agent. Separately, Parloa's Consumer Patience Index, a survey of 1,001 U.S. consumers conducted by independent research firm Propeller Insights, found that nearly a third of consumers would switch brands entirely just to avoid being put on hold. Parloa's approach is built on the idea that completing an interaction, rather than stalling partway through it, can turn automation into customer loyalty instead of frustration.

"The research confirms what we've all experienced ourselves — consumer expectations are high, and brand loyalty is fragile," said Chris Silver, Chief Revenue Officer, Parloa. "They need to have their issue solved, the first time, on their preferred channel and with no unnecessary delays. Legacy automation couldn't do it; Parloa's can, and with our TELUS Digital partnership, we're excited to show the innovative enterprise what's possible in agentic customer experience."

Automation in CX can be most effective when enterprises and customers trust the platform delivering it. Parloa's platform recently earned SAP's endorsed app premium certification, a distinct category within SAP's partner ecosystem reserved for solutions that meet added security, testing and performance standards. The platform runs on Azure and supports multiple AI models, including OpenAI's GPT series, giving enterprises flexibility as the technology evolves. The company, with enterprise operations across Europe and the U.S., has built six years of deployment experience serving businesses across banking and financial services, insurance, utilities, telecommunications and media, retail, logistics, travel, and healthcare and life sciences. Parloa builds its agents to meet enterprise compliance standards, including GDPR, ISO 27001 and SOC 2, with every interaction designed to help protect personal information.

Expanding TELUS Digital's AI-powered CX solutions

As enterprises adopt agentic AI platforms across their customer service operations, TELUS Digital believes a single tool rarely covers every need and that enterprises benefit from matching the right capability to the right type of interaction.

"When contact centers get buried in high volume, repetitive interactions, we often see cost to serve climb without the customer experience improving," said Will Mayo, Global Senior Vice President of Growth, TELUS Digital. "What stands out to us about Parloa is that its agents are designed to take care of routine requests from start to finish, and hand-off to a person when a conversation gets more complex. Parloa is built to work through partners like TELUS Digital, which can act as a one-stop shop from strategy to implementation and scaled delivery. This gives our clients another way to move eligible, high volume interactions to automation while keeping people available for conversations that need their empathy and knowledge."

The Parloa partnership is the newest addition to TELUS Digital's AI capabilities for customer experience. TELUS Digital's conversational AI solutions combine voice, generative AI and agentic automation, so AI agents can handle routine requests across channels and languages and pass the conversation to a human agent, with full context, when the interaction needs a person.

To support human agents, TELUS Digital's AI-powered agent tools can analyze customer interactions to support quality and coaching, and offer real-time guidance during live conversations. TELUS Digital's proprietary Fuel iX™ Agent Assist gives agents real-time knowledge and answers, while Fuel iX Agent Trainer uses AI-generated voice and chat simulations to help new agents practice customer conversations before taking live calls. TELUS Digital can connect these solutions to clients' contact center platforms, customer relationship management (CRM) systems and backend systems. The company also offers CX consulting to identify where AI fits, along with customer service and contact center management teams to run and optimize a blend of AI and human support.

The Parloa partnership extends TELUS Digital's AI-powered CX solutions for enterprise clients in industries including telecommunications, retail, travel and hospitality, media, banking, financial services and insurance, and healthcare, supported by a global delivery footprint of 83,000+ team members across 35+ countries.

To learn more about TELUS Digital's AI-powered CX solutions, visit:

For more information on Parloa's agentic AI platform for CX, visit: parloa.com

Frequently asked questions

- What is Parloa and what does it do?

Parloa is an agentic AI platform built to let AI agents handle customer interactions such as authentication, bookings, payments and order inquiries from beginning to end. The platform escalates to a person when a conversation calls for more judgment, and every interaction is designed to protect personal information while meeting compliance standards including built to support GDPR and certified to ISO 27001 and SOC 2. Parloa also holds SAP's endorsed app premium certification, a distinct category within SAP's partner ecosystem for solutions that meet added security, testing and performance standards. The platform is built around turning every resolved interaction into lasting customer loyalty, not just a closed ticket.

- Why did TELUS Digital partner with Parloa?

TELUS Digital partnered with Parloa to expand its portfolio of AI capabilities for customer experience with end-to-end customer service automation solutions. The partnership pairs Parloa's agentic AI platform, used by enterprises in insurance, retail, travel and healthcare, with TELUS Digital's CX expertise, industry relationships and global delivery footprint. It also complements the AI solutions TELUS Digital already offers, giving enterprises another way to move eligible, high volume interactions to automation while keeping people available for the conversations that need them.

- What problem does agentic AI solve for contact centers?

Contact centers often carry a heavy load of repetitive, transactional interactions, such as identity verification, bookings and payment questions, that drive up the cost to serve without making the experience any better for the customer. Many AI tools can answer part of a question but still hand the interaction back to a person to finish, so the customer effectively waits twice. Parloa's own research found that fewer than 9% of chatbot conversations reach resolution, illustrating how common that gap is. Agentic AI platforms like Parloa are built to complete these interactions fully on their own, reserving human involvement for the conversations that need empathy and judgment.

- Who implements Parloa for TELUS Digital's enterprise clients?

Enterprises that choose to deploy Parloa can contract directly with the company for the platform itself and engage TELUS Digital for implementation, integration, change management, managed services and other professional services. TELUS Digital serves as an implementation partner, introducing prospective and current enterprise clients to Parloa's AI agent platform and helping them put it into production at scale.

- What does TELUS Digital's approach to AI in customer experience look like? TELUS Digital's AI portfolio for customer experience pairs its own Fuel iX suite with technology partnerships, covering conversational AI agents, real-time guidance and coaching for human agents, and agent training. Parloa expands that portfolio with autonomous resolution for eligible transactional interactions. These sit alongside TELUS Digital's broader CX practice, spanning consulting-led AI transformation, contact center operations and technology implementation for enterprise clients across industries including telecom, banking and financial services, media and entertainment, hi-tech, retail, travel, transport and hospitality, software and platforms, energy and utilities, healthcare, and insurance, backed by a global delivery footprint of 83,000+ team members across 35+ countries.

- Why should enterprises choose TELUS Digital as a Parloa implementation partner?

Highlights:

- Impressive silver and gold recoveries achieved from the latest round of optimised cyanide leach testwork at the Maverick Silver Project, demonstrating rapid silver and gold extraction within 24 to 48 hours.

- The Company is undertaking a range of metallurgical testwork to optimise silver-gold extraction and provide optionality in processing pathways that will be considered in future studies.

- Sample 1 (LT15) achieved rapid silver and gold extraction within 24 hours under the same leach conditions (P80 53µm grind; 5,000 ppm initial / 2,500 ppm-maintained NaCN; no lead nitrate): 

- Head assay results, 84.5% silver and 83.6% gold recovery with peak recoveries indicated between 0 and 48 hours.

- A lower-reagent optimisation test on Sample 2 (LT22) also delivered rapid silver extraction (P80 53µm grind; 3,000 ppm initial / 1,500 ppm-maintained NaCN; 500 ppm lead nitrate): 

- Head assay results, 87.7% silver recovery and 87.5% gold recovery with peak recoveries indicated between 0 hours and 48 hours.

- Possible upside exists for silver and gold recoveries at 24 and 48 hours, with Sample 1 interim solution assays indicating higher extraction percentages than the reported recoveries calculated using final head assay grades.

- Silver extraction accelerated under elevated cyanide, with further optimisation targeting the optimal balance between recovery and reagent consumption.

- Tank-leach/CIL may provide greater flexibility for potential antimony recovery. The Company is in the process of working towards a maiden antimony Mineral Resource Estimate.

- Continued active U.S. Government (Department of Commerce) engagement, focused on large-scale domestic development and maximising U.S. production of silver and critical minerals including antimony and gold, further reinforces the strategic rationale for also evaluating higher recovery tank leach/CIL development pathways at Maverick.

PERTH, Australia, Oct. 14, 2026 /PRNewswire/ -- Sun Silver Limited (ASX: SS1; OTCQX: SSLVF) ("Sun Silver" or "the Company") is pleased to report highly encouraging results from its ongoing metallurgical activities for the Maverick Silver Project in Nevada, USA ("Maverick" or "the Project").

Sun Silver Managing Director, Andrew Dornan, said:

"These results continue to demonstrate the strong metallurgical characteristics of Maverick, with rapid silver and gold extraction within just 24 hours providing further confidence in the Project's development potential. The results highlight clear opportunities to further optimise recoveries, reagent consumption and processing conditions as we evaluate the optimal development pathway. With active U.S. Government engagement focused on large-scale domestic development, maximising U.S. metal production and strengthening critical mineral supply chains, we continue to evaluate processing options capable of maximising silver, gold and potential antimony recovery."

Metallurgical Testwork - Update

As part of the Company's larger ongoing metallurgical testwork program evaluating and optimising potential processing pathways for the Project, the work detailed within this announcement focused specifically on accelerating silver extraction within the first 48 hours through optimisation of cyanide concentration, lead nitrate addition, dissolved oxygen and grind size.

This series of testwork was devised to build on and complement the previous exceptional silver-gold recovery results from Intermittent Bottle Roll and Cyanide Leach testwork that provided an initial estimate of heap-leach and tank-leach recoveries, respectively, and showed no evidence of preg-robbing .

Metallurgical testwork was designed, undertaken, managed and reviewed by Independent Metallurgical Operations ("IMO"), a subsidiary of SGS. Samples utilised for this testwork were derived from the same composites of the initial testwork program1. The tests were conducted in deionised water, so it mitigates against known chloride ion concentration variations in Perth tap water.

A total of 242 intervals of half diamond drill core were derived from existing diamond core samples, comprising oxide and transitional mineralisation. Two composite samples were prepared:

- Composite sample 1: 147kg total weight

- Composite sample 2: 127kg total weight

Five cyanide leach bottle-roll tests were undertaken on Sample 1 and six tests on Sample 2, allowing the Company to assess the effect of varying reagent regimes and grind sizes on silver and gold extraction.

The standout result was achieved from Sample 1 (LT15), which demonstrated rapid extraction of both silver and gold under the LT15 leach conditions.

Head assay results, 84.5% silver and 83.6% gold recovery with peak recoveries indicated between 0 hours and 48 hours.

The rapid extraction of both silver and gold within the first 24 to 48 hours is particularly encouraging for the Company's assessment of a conventional tank-leach/CIL processing flowsheet, where recovery, leach kinetics and residence time are important inputs into process design and economic evaluation.

Strong Recoveries at Reduced Cyanide Dosage

Importantly, a subsequent optimisation test on Sample 2 (LT22) evaluated silver-gold recovery under a more moderate cyanide regime combined with a reduced lead nitrate dosage.

Head assay results, 87.6% silver recovery and 87.5% gold recovery

The ongoing program will seek to determine whether a balanced combination of cyanide and lead nitrate can deliver comparable metallurgical performance to the higher cyanide regime while reducing overall reagent consumption and operating costs.

Lead Nitrate and Early-Stage Leach Kinetics

Comparative tests assessed the introduction of lead nitrate as a potential means of accelerating silver and gold leach kinetics.

Testwork shows that the addition of lead nitrate under standard cyanide conditions accelerated silver extraction in both samples, supporting further assessment of lead nitrate as part of reagent optimisation.

At elevated cyanide concentrations, the incremental benefit of lead nitrate reduced materially by 48 hours. In Sample 1, lead nitrate accelerated early silver extraction, while the 48-hour silver recoveries were similar between the tests, indicating that its principal benefit under the conditions tested was accelerated early-stage extraction.

Silver Leach and Reagent Optimisation

The Maverick testwork demonstrates the impact of cyanide concentration on the rate of silver extraction.

Silver cyanidation can require more intensive leach conditions than conventional free-milling gold cyanidation. Silver extraction can be sensitive to free cyanide concentration, dissolved oxygen, mineralogy and leach residence time, making optimisation of the overall reagent regime an important component of flowsheet development.

These results highlight an important optimisation opportunity for Maverick: determining the optimum balance between cyanide concentration, lead nitrate dosage, dissolved oxygen and residence time to maximise silver and gold recovery and leach kinetics while minimising reagent consumption and processing costs.

Tank Leach Provides Potential High-Recovery Development Pathway

The latest results provide further support for Sun Silver's assessment of a conventional tank-leach/CIL processing pathway, alongside heap-leach development scenarios currently being evaluated for Maverick.

The ability to achieve 84.5% silver and 83.6% gold recovery within only 24 hours (Sample 1 results) provides an important technical basis for evaluating a high-recovery processing configuration.

The Company considers the speed of extraction particularly encouraging. The majority of recoverable silver and gold in the standout test was extracted within the first 24 hours. This provides important information for ongoing optimisation of residence time, plant configuration and processing economics.

Recovery Disclosure: Silver and gold extraction percentages reported at interim time intervals (including 24 and 48 hours) represent indicative point-in-time calculated extractions, determined from solution assays collected at the relevant sampling time and the back-calculated head grade. Accordingly, interim extraction results are indicative of metallurgical performance at the stated point-in-time and should not be interpreted as final or ultimate recoveries.

U.S. Strategic Importance and Optionality for Antimony Recovery

Sun Silver continues active engagement with various U.S. Government including Department of Commerce and Permitting Council regarding Maverick's potential role in strengthening domestic silver and critical-mineral supply chains, including potential pathways for U.S. Government support for the Project.

These engagements reflect a strategic focus on large-scale domestic development and maximising the recovery and production of U.S. sourced metals. Together with Maverick's substantial silver-gold Mineral Resource and emerging antimony potential, this reinforces the importance of evaluating development scenarios capable of maximising metal recovery and production at scale.

Accordingly, the Company is continuing to evaluate both heap-leach and higher-recovery tank-leach/CIL processing pathways, including the potential for a tank-leach/CIL flowsheet to provide greater flexibility for potential future antimony recovery. All development options remain open, with metallurgical, technical and economic investigations continuing to determine the optimal development pathway for Maverick.

Next Phase of Tank-Leach / CIL Metallurgical Optimisation

The latest testwork has identified several clear opportunities to further optimise the Maverick processing flowsheet, with the next phase of metallurgical work focused on maximising recoveries while reducing reagent consumption, grind requirements and processing costs.